Navigation Links
PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
Date:7/10/2012

mmercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required u
'/>"/>
SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
2. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
3. Puma Biotechnology Announces Completion of Private Placement
4. Animal Biotechnology - Technologies, Markets and Companies
5. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
6. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
7. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
10. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
11. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... NORTH BRUNSWICK, N.J. , May 28, 2015 ... that PDS0101, a cancer immunotherapy treatment targeting HPV-16, ... patients.  Currently, pre-cervical cancer is ... could offer a simple and effective non-surgical alternative. ... body,s defense mechanisms (T-cells) to recognize, target, and ...
(Date:5/28/2015)... Md. , May 28, 2015  GenVec, Inc. ... and CEO, Douglas J. Swirsky , will present ... Conference at 11 a.m. EDT on Thursday, June 4, ... of Mr. Swirsky,s presentation will be available at the ... be available on GenVec,s website.  To access, visit ...
(Date:5/28/2015)... 28, 2015 Glenn Keet, CEO of ... Landscape of EMR/EHR Clinical Data Integration with EDC Systems ... in Washington, DC on June 14th-18th. , During the ... EMR/EHR systems with EDC, and will examine the value ... eSource and electronic health records/electronic medical records integration. ...
(Date:5/28/2015)... 28, 2015 American Process Inc. ... Ridge, TN) recently signed a joint agreement ... plastic resins using nanocellulose, a rapidly emerging high ... printing is the limited number of feedstock materials ... strength to printed parts for load bearing applications. ...
Breaking Biology Technology:PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2GenVec To Present At The Jefferies Healthcare Conference 2Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 2American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 3
... , JERUSALEM, August 25 ... of oral delivery,systems, today announced that it is the ... Delivery Technology Innovation Award. , ... oral,delivery systems for drugs and vaccines delivered via injection. ...
... NEW YORK, Aug. 25 NeoStem Inc. (NYSE Amex: ... long-term storage of adult stem cells for future medical need, announced ... invited to participate in the 2009 World Stem Cell Summit to ... Dr. Smith will participate on the panel, "Cord Blood and ...
... GAITHERSBURG, Md., Aug. 25 GenVec, Inc. (Nasdaq: GNVC ... Business Innovation and Research (SBIR) grant from the National Institute of ... (NIH) to support the development of GenVec,s vector production technology. ... 0081205/DC50112LOGO ) , , Funds ...
Cached Biology Technology:Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award 2Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award 3NeoStem CEO to Participate in 2009 World Stem Cell Summit on September 23rd 2NeoStem CEO to Participate in 2009 World Stem Cell Summit on September 23rd 3GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development 2
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
(Date:4/27/2015)... ATLANTA , April 27, 2015  For more ... and trade show has been the premier worldwide event ... Systems 2015 is a must-attend event for any local, ... insight into the emerging commercial markets and current applications ... and innovations of this projected $48 billion industry, and ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... Center have identified how nanoparticles from diesel exhaust damage lung ... for people susceptible to airway disease. The scientists ... the genetic make-up of the affected individual. "We ... in polluted areas and why others don,t," said lead author ...
... young people engage in, has associated adverse health risks ... controlling overall alcohol usage, states an editorial in ... link only) http://www.cmaj.ca/embargo/cmaj110029.pdf . "Given the many ... we need a national strategy for controlling overall alcohol ...
... eating a big breakfast help weight loss or is ... confusing but new research published in BioMed Central,s open ... through these apparently contradictory reports. Dr Volker Schusdziarra, ... study on over 300 people who were asked to ...
Cached Biology News:Findings on pollution damage to human airways could yield new therapies 2
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: